Cryoport's CGT Pipeline Gains Momentum, but Profitability Still Unproven

What happened

Cryoport shares have surged 82% year-to-date as a Seeking Alpha article highlights adjusted EBITDA profitability in Q2 2026, positive trailing operating cash flow of $8 million, and an expected five new cell and gene therapy (CGT) commercial approvals in 2026. Management also reports a 15% year-over-year increase in Phase 3 trials to 94, supporting the company's claim of strong pipeline momentum. However, the latest regulatory filings (as of September 2025) show the company remains structurally loss-making, with negative interest coverage and a history of large impairments, making the recent profitability a single quarter that needs confirmation. The master report's stance of 'WAIT' reflects concerns that the market has already priced in a successful turnaround, leaving limited margin of safety given volatile free cash flow and a DCF that implies negative intrinsic value. While the new pipeline data and EBITDA breakeven are positive watch items, sustained profitability and positive free cash flow over multiple quarters are necessary to upgrade the thesis.

Implication

The reported Q2 2026 adjusted EBITDA profitability and positive operating cash flow, if verified in upcoming SEC filings, would mark a significant milestone that supports a potential upgrade from WAIT to BUY. However, given Cryoport's history of impairments and negative interest coverage, one quarter of profitability is insufficient to establish a durable trend, especially since the company has burned cash in recent years. The expected five new CGT approvals in 2026 could accelerate revenue growth from commercial therapies, but these approvals are subject to regulatory timing and may not translate into immediate high-margin logistics demand if adoption is slow. The increase in Phase 3 trials to 94 is encouraging, but the conversion rate to commercial therapies has historically been gradual, and the company's heavy infrastructure may continue to weigh on operating leverage. Therefore, investors should monitor upcoming quarterly results for confirmation of sustained positive EBITDA, improving free cash flow, and no further capital raises, while the current high valuation relative to negative DCF implies limited upside despite the positive pipeline narrative.

Thesis delta

The thesis delta is modestly positive: the news of EBITDA profitability and an expanding Phase 3 pipeline addresses some watch items, but it does not yet overcome the structural concerns of negative DCF value and historical execution issues. The overall stance remains WAIT, pending confirmation of sustained profitability and cash flow in subsequent quarters.